Articles On Noxopharm (ASX:NOX)

Highlights Materials sector showed resilience amid broader market caution Healthcare shares delivered renewed momentum on the ASX Energy and utility stocks faced pressure from global uncertainty The Australian share ma...

ASX a whiter shade of pale as oil, yields and geopolitics bite again Utilities drained of life while materials avoid the carnage Gold stocks a touch anaemic as Dracula Day arrives right on cue   Today, “the world” observed a day dedicated...

Novel immune activation approach shown in ex vivo and in vivo experiments Builds on breakthrough immune system discovery Market projected to reach US$185 billion by 2035 Noxopharm (ASX:NOX) has jumped by 40% after it obtained new...

Fisher & Paykel Health shrugs off flu market weakness Aroa Biosurgery flags further revenue growth after a “breakout” year Ryman Healthcare rides the aged care boom   Unlike their nation’s perennially grounded Kiwi birds, New Zealand...

Highlights Small-cap ASX stocks linked to biotech, battery technology, energy, and resources dominated early market movement. Exploration updates, regulatory approvals, and strategic appointments continued driving volatility across eme...

Stockhead’s new daily column Morning Feed plates up early ASX sharemarket movers, ASX announcements and company news, giving investors a quick serving of market action and updates from selected ASX-listed companies.   Elevenses Your ASX top...

AI is honing the commercial endeavours of small caps including Algorae Pharmaceuticals and Dorsavi Rhythm Biosciences presents more ‘real world’ bowel cancer assay evidence Noxopharm girds for crucial FDA meeting   Artificial intelligence...

Preparations underway for US FDA pre-IND meeting Move to boost SOF-SKN treatment commercial potential Global clinical research organisation signed Global CLE market is worth more than US$3.3 billion and Clinical-stage Australia...

Hello, and welcome to HotCopper‘s Market Open for Wednesday, Week 19, I’m Colin Sandell-Hay The ASX 200 is tipped to potentially rebound on positive Wall Street news overnight and a 3.83% fall in Brent crude prices.  Listen to the Hot...

Fitch Group subsidiary BMI says local drug makers should be immune from the White House’s proposed 100% pharma tariff Brokers pare their Cochlear valuations Arovella ginger group abandons its board putsch   Australian pharma companies hav...

ASX closed down 0.04% after early dip, failing to fully follow through on some arvo promise Energy dropped almost 1%, making it the worst sector as oil tension weighs Tech on a six-day streak while Rio held firm; broader market stalled  ...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX dips 0.26% as fuel jitters and strong jobs keep conviction in check Tech rips higher, led by WiseTech Global and Xero, bucking the broader weakness Viva refinery fire rattles energy sentiment while Bison Resources charges onto the boar...

Highlights Leadership transition announced within biotech segment alongside operational updates. Exploration progress continues across lithium and gold-focused projects. Small-cap activity reflects ongoing engagement within...

Orthocell shares soar 20% after the go-ahead to sell flagship Remplir product to US defence and vet affairs hospitals Telix seals monster $840 million debt capital raising Forget Lego – Genetic Signatures finds its own Danish building bloc...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script Nyrada ch...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

After a strategy revamp, Noxopharm is targeting inflammatory diseases – lupus in particular Affecting five million people, lupus has proved a tricky disease to tackle The company is pondering a phase II trial, most likely in skin lupus No...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

ASX rises 0.22pc after flat day of trade Earnings reports from big cap companies weighed heavy Gains and losses equalised after lunch for steady end to day ASX edges higher on earnings equilibrium It was another tale of heroes and villai...

Ansell says it has reacted swiftly to new tariff imposts by raising prices in June, with more increases to come LTR Pharma reports satisfaction clean sweep in an erectile dysfunction trial Argent does the ARD yards with US in vivo trial R...

 Advances on research and development tax incentives are proving a popular source of ancillary financing Audeara shares surge up to 36% on China deal Bell Potter halves its Syntara valuation   With traditional equity fundraising conditio...

Noxopharm (ASX: NOX) has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN. The safety steering committee confirmed the dose level was safe and tolerable, enabli...

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Gold stocks drive gains with index climbing 3.3pc ASX hits new record close at 8843 points Broad market strength with 10 of 11 sectors up Solid gains supported by gold It was another picturesque day of trading on the ASX today, rising st...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Australia’s S&P/ASX 200 rose 2.36% in July, posting gains of almost 9% so far for CY25 Health care had a dose of good medicine, rebounding 9% to be best performing sector for month Santa Fe Minerals jumps 739% in July after executing d...

Copper prices crash 20pc Materials sector undercuts market, down 2.57pc Info tech rally not enough to push ASX into positive territory   Tech rally fails to lift resources The ASX staged a steady recovery through the day to finish down ju...

Energy stocks climb as oil ticks up 2pc ASX rallies late to climb 0.08pc Gold stocks slide despite recovering gold price   ASX lifts as clouds part for energy sector The ASX was in a decidedly bad mood today, hanging out in negative terri...

A trade deal between the EU and US has staved off the worst tariff fears Telecoms led gains alongside financials and healthcare Banking stocks end bearish run, gaining 0.81pc   ASX holds its nerve After a shaky start to trade this morning...

ASX beats hasty retreat from new record high, down 0.79pc Info tech rises against the tide, adding 0.85pc Banks and financial stocks struggle alongside materials sector, leading losses Info tech fires up despite dour market The ASX unwoun...

Lumos Diagnostics says its US distribution deal is worth up to $487 million Impedimed’s US device sales are on a roll Noxopharm treats its first lupus trial patient   In one of the “largest distribution deals of its type” by an ASX-listed...

Noxopharm Ltd (ASX:NOX) has got its HERACLES trials out the gates in Week 29, dosing a preliminary patient in the first-in-human use of its SOF-SKN topical drug candidate targeting TLR7/8 for autoimmune diseases. Listen to the HotCopper...

EchoSolv enters Mayo’s gauntlet for FDA nod Echo’s AI flags heart failure before it hits the fan Other ASX stocks that have trialled with Mayo   On July 1, Echo IQ released an announcement that made cardiologists sit a little straighter....

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injury Preclinical work has shown a significant reduction in secondary brain injury and cardiac damage CEO James Bonnar spent 15 years a...

Clarity is poised to launch its second phase III prostate cancer imaging trial LTR Pharma shares swell 30% on the back of local chemist deal   Trajan shares measure up at 70% above their current value   In launching its second phase III t...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...

Global drug companies again are on the alert after Donald Trump reiterated his intention to impose a pharma tariff rumoured to be 25% No sweat! as Botanix raises $40 million in a placement Imricor’s ablation news lauded as a “truly groundb...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...